Hannah Clarke

The NMPA’s approval was supported by data from the phase 3 EV-302 trial.

Sunobinop resulted in a reduction in urinary urgency, urinary frequency, and incontinence episodes over the treatment period compared with placebo.

The application is supported by data from the pivotal phase 3 ARANOTE trial.

The J-code became effective on January 1, 2025.

“However, it was informative to uncover such a high number of metastatic findings in a well-defined cohort of patients resembling the EMBARK trial population that was supposed to only include those without metastases," says Adrien Holzgreve, MD, MHA.

The detection rate for [99mTc]Tc-HYNIC-iPSMA SPECT imaging was 77.5%.

Among those with Signature II tumors, overall survival was improved among those who received nivolumab compared with those who received everolimus.

The BLA for TLX250-CDx was initially submitted to the FDA in June 2024.

Catch up on all the notable drug and device approvals in urology over the past year.

As the year comes to a close, we revisit some of this year’s top content on the management of renal cancer.

The approval is supported by data from the phase 3 CheckMate-67T trial.

As the year comes to a close, we revisit some of this year’s top content on kidney stone management.

The SURE procedure also demonstrated significantly better outcomes on the study’s secondary end points of stone clearance and residual stone volume.

The approval of vibegron is supported by data from the phase 3 COURAGE trial.

The alert was issued to clarify that the devices should not be used for suction and irrigation.

The investigators found a positive correlation between PSA levels and SUVmax.

“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies for [prostate cancer]," write the authors.

Initial data from the trial are expected to be released in the first half of 2025.

The redePHine trial is expected to launch in the first half of 2025.

The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.

Pluvicto was approved by Health Canada in August 2022.

From baseline to 1 year, the Ki-67 index decreased in the dietary intervention cohort by 15% and increased in the control cohort by 24%.

Age, race, and hormonal contraceptive use did not significantly impact the efficacy of sildenafil cream, 3.6%, in female sexual arousal disorder.

A final decision on marketing authorization is anticipated for Q1 of 2025.

“If approved, this approach has the potential to transform the treatment paradigm in prostate cancer, offering patients with localized disease an effective treatment option that may reduce the risk of disease recurrence," says Glen Gejerman, MD, MBA.

The primary aims for the EVANESCE-II trial are to confirm the safety of the FemPulse System and to establish noninferiority to first-line tolterodine.

Specifically, 90% of patients in the HIFU arm vs 86% of patients in the radical prostatectomy arm were free from subsequent definitive treatment at 30 months.

Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy for patients with BCG-unresponsive high-risk NMIBC.

The clearance is supported by data from the PRESERVE trial, which evaluated the safety and effectiveness of the NanoKnife System in patients with intermediate-risk prostate cancer.

The overall complete response rate was 74.5% (95% CI, 65.4%-82.4%).